Page last updated: 2024-11-08

rwj 37947

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID445393
CHEMBL ID417656
SCHEMBL ID677428
MeSH IDM0289027

Synonyms (13)

Synonym
sulfamic acid 2,3-o-(1-methylethylidene)-4,5-o-sulfonyl-beta-fructopyranose ester
DB02894
1EOU
bdbm13057
rwj-37947
[(1s,2s,6r,9s)-11,11-dimethyl-4,4-dioxo-3,5,8,10,12-pentaoxa-4$l^{6}-thiatricyclo[7.3.0.0^{2,6}]dodecan-9-yl]methyl sulfamate
[(3ar,5as,8as,8bs)-7,7-dimethyl-2,2-dioxidotetrahydro-5ah-[1,3,2]dioxathiolo[4,5-d][1,3]dioxolo[4,5-b]pyran-5a-yl]methyl sulfamate
chembl417656 ,
SCHEMBL677428
((3ar,5as,8as,8bs)-7,7-dimethyl-2,2-dioxidotetrahydro-3ah-[1,3,2]dioxathiolo[4,5-d][1,3]dioxolo[4,5-b]pyran-5a-yl)methyl sulfamate ,
Q63390535
[(1s,2s,6r,9s)-11,11-dimethyl-4,4-dioxo-3,5,8,10,12-pentaoxa-4lambda6-thiatricyclo[7.3.0.02,6]dodecan-9-yl]methyl sulfamate
PD059765
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CARBONIC ANHYDRASE II (CA II)Homo sapiens (human)IC50 (µMol)0.03600.03600.03600.0360AID977608
Carbonic anhydrase 12Homo sapiens (human)Ki0.03600.00021.10439.9000AID1796980
Carbonic anhydrase 1Homo sapiens (human)Ki0.03600.00001.372610.0000AID1796980
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)0.03600.00021.10608.3000AID47745
Carbonic anhydrase 2Homo sapiens (human)Ki0.34920.00000.72369.9200AID1796980; AID239219; AID239220
Carbonic anhydrase 4Homo sapiens (human)Ki0.03600.00021.97209.9200AID1796980
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki0.03600.00001.27259.9000AID1796980
Carbonic anhydrase 7Homo sapiens (human)Ki0.03600.00021.37379.9000AID1796980
Carbonic anhydrase 9Homo sapiens (human)Ki0.03600.00010.78749.9000AID1796980
Carbonic anhydrase 13Mus musculus (house mouse)Ki0.03600.00021.39749.9000AID1796980
Carbonic anhydrase 14Homo sapiens (human)Ki0.03600.00021.50999.9000AID1796980
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki0.03600.00001.34129.9700AID1796980
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 2Homo sapiens (human)Kd0.01000.00000.41575.5500AID266012
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID112978Compound was tested for the effective dose (ED50) for each time point in Mice. 95% confidence limits are given in parentheses 1 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID112982Compound was tested for the effective dose (ED50) for each time point in Mice. 95% confidence limits are given in parentheses 24 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID239219Inhibitory constant value for Carbonic anhydrase II in human determined in esterase assay2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform.
AID50190Inhibition concentration by inhibition of carbonic anhydrase from brain in Rat. 95% confidence limits are given in parentheses.1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID21041pH 7.4 value at 7.35 pH1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID266012Binding affinity to human CA2 by ThermoFluor assay2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements.
AID50188Inhibition concentration by inhibition of carbonic anhydrase from blood in Rat. 95% confidence limits are given in parentheses.1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID25832Pharmacokinetic parameter :The dissociation constant values at 25 degrees C, obtained by potentiometric titration.1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID178723Compound was tested for the effective dose (ED50) for each time point in Rats. 95% confidence limits are given in parentheses 12 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID112981Compound was tested for the effective dose (ED50) for each time point in Mice. 95% confidence limits are given in parentheses 2 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID178724Compound was tested for the effective dose (ED50) for each time point in Rats. 95% confidence limits are given in parentheses 16 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID19675Partition coefficient (logP)1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID112980Compound was tested for the effective dose (ED50) for each time point in Mice. 95% confidence limits are given in parentheses 16 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID139910Activity against maximal electroshock seizures in mice, 4 hr following oral administration of 35 mg/kg of compound1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID178866Compound was tested for the effective dose (ED50) for each time point in Rats. 95% confidence limits are given in parentheses 8 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID47745Compound was tested for inhibition of human carbonic anhydrase (hCA II)2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II.
AID21037p value at 7.35 pH1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID15879Partition coefficient (logP)1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID50335Inhibition concentration by inhibition of carbonic anhydrase from myelin in Rat. 95% confidence limits are given in parentheses.1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID139905Inhibition of maximal electroshock seizures in mice, 4 hr following 10 mg/kg p.o. administration.1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID15964Partition coefficient (logP)1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID239220Inhibitory constant value for Carbonic anhydrase II in human determined in pH-shift assay2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform.
AID50337Inhibition concentration by inhibition of carbonic anhydrase from synaptosomes in Rat. 95% confidence limits are given in parentheses.1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID23719Pharmacokinetic parameter :log P7.4 log P value at pH 7.41998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID178726Compound was tested for the effective dose (ED50) for each time point in Rats. 95% confidence limits are given in parentheses 24 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID178722Compound was tested for the effective dose (ED50) for each time point in Rats. 95% confidence limits are given in parentheses 1 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID178725Compound was tested for the effective dose (ED50) for each time point in Rats. 95% confidence limits are given in parentheses 2 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID112979Compound was tested for the effective dose (ED50) for each time point in Mice. 95% confidence limits are given in parentheses 12 hr1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID50338Inhibition concentration of the compounds were determined by inhibition of carbonic anhydrase from kidney in Rat. 95% confidence limits are given in parentheses.1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID131508Effective dose against maximal electroshock seizures in mice, at 4 hr following oral administration of 10 mg/kg of compound1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID112983Compound was tested for the effective dose (ED50) for each time point in Mice. 95% confidence limits are given in parentheses 4 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID178864Compound was tested for the effective dose (ED50) for each time point in Rats. 95% confidence limits are given in parentheses 4 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID178865Compound was tested for the effective dose (ED50) for each time point in Rats. 95% confidence limits are given in parentheses 48 Hour1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2002The Biochemical journal, Feb-01, Volume: 361, Issue:Pt 3
Crystal structure of human carbonic anhydrase II complexed with an anti-convulsant sugar sulphamate.
AID1811Experimentally measured binding affinity data derived from PDB2002The Biochemical journal, Feb-01, Volume: 361, Issue:Pt 3
Crystal structure of human carbonic anhydrase II complexed with an anti-convulsant sugar sulphamate.
AID1796980CA Inhibition Assay from Article 10.1021/jm060807n: \\Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide anal2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's5 (83.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]